Back to JAZZ
Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
1 competitor in Refractory Ewing Sarcoma
View Full LandscapeDrug Information
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Regulatory Approvals
EMA5/29/2026
Zepzelca
Zepzelca, in combination with atezolizumab, is indicated for the maintenance treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first-line induction therapy with atezolizumab, carboplatin and etoposide.
Orphan
View on EMADrug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
